Related Experiment Video
Updated: Jul 17, 2026
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Neuromuscular effects of sevoflurane in myasthenia gravis patients
1Department of Anesthesiology, Fukuoka University School of Medicine, Fukuoka, Japan. nitahara@fukuoka-u.ac.jp
Background:
Little information is available regarding the neuromuscular effects of sevoflurane in patients with myasthenia gravis (MG). We evaluated the neuromuscular effects of sevoflurane alone in patients with MG and in those with normal neuromuscular transmission.
Methods:
Sixteen patients with generalized type MG (MG group) and 12 otherwise healthy patients (control group) entered into this study. Anaesthesia was induced with propofol, fentanyl, and midazolam followed by nitrous oxide in oxygen. Neuromuscular monitoring was recorded from the adductor pollicis muscle using electromyography with train-of-four stimulation of the ulnar nerve. After a stabilization period, and before sevoflurane administration, baseline T4/T1 was obtained and MG patients were classified as non-fade MG group (baseline T4/T1 > or = 0.90) (n = 10) and fade MG group (baseline T4/T1 < 0.90) (n = 6). End-tidal sevoflurane concentration was kept constant at 1.7% for 30 min and doubled thereafter to 3.4% and maintained for a further 30 min.
Results:
Sevoflurane produced a concentration-dependent decrease in T1 and T4/T1 values. At 3.4% sevoflurane, T1 and T4/T1 decreased significantly from baseline values in all three groups. From baseline until the patient woke up from anaesthesia, the T4/T1 of the fade MG group was significantly lower than the other groups. At the end of anaesthesia, T4/T1 returned to values similar to the baseline in all three groups.
Conclusions:
During sevoflurane anaesthesia, concentration-dependent inhibition of neuromuscular transmission was observed in MG and control patients. The inhibitory effects of sevoflurane were more prominent in MG patients with baseline T4/T1 <0.90.
Insights
Sevoflurane impacts neuromuscular transmission in myasthenia gravis (MG) patients, causing greater inhibition in those with baseline neuromuscular dysfunction. Recovery of neuromuscular function was observed in all groups post-anesthesia.
Area of Science:
- Anesthesiology
- Neuromuscular Pharmacology
- Clinical Neurology
Background:
- Limited data exists on sevoflurane's neuromuscular effects in myasthenia gravis (MG).
- This study investigates sevoflurane's impact on neuromuscular transmission in MG patients versus healthy controls.
Purpose of the Study:
- To evaluate the neuromuscular effects of sevoflurane alone in patients with myasthenia gravis (MG).
- To compare these effects with those in patients exhibiting normal neuromuscular transmission.
Main Methods:
- 16 generalized MG patients and 12 healthy controls were studied.
- Neuromuscular monitoring utilized electromyography with train-of-four stimulation.
- MG patients were classified based on baseline T4/T1 ratio (fade vs. non-fade).
- Sevoflurane concentrations were maintained at 1.7% then 3.4% end-tidal.
Main Results:
- Sevoflurane caused a concentration-dependent decrease in neuromuscular transmission (T1 and T4/T1).
- At 3.4% sevoflurane, significant decreases were observed in all groups.
- The 'fade' MG group showed significantly lower T4/T1 values compared to others.
- Neuromuscular function returned to baseline levels by the end of anesthesia.
Conclusions:
- Sevoflurane induces concentration-dependent neuromuscular blockade in both MG and control patients.
- The inhibitory effects were more pronounced in MG patients with pre-existing neuromuscular transmission deficits (baseline T4/T1 < 0.90).
Related Concept Videos
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...